The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
Abstract Among blood cancers, multiple myeloma (MM) represents the second most common neoplasm and is characterized by the accumulation and proliferation of monoclonal plasma cells within the bone marrow. Despite the last few decades being characterized by the development of different therapeutic st...
Saved in:
| Main Authors: | Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli, Jessica Faletti, Davide Capoferri, Raffaella Marcheselli, Margherita Sciumè, Marco Presta, Antonio Sacco, Aldo M. Roccaro |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-024-03217-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR
by: Jinhao Chen, et al.
Published: (2025-03-01) -
Decoding FGF/FGFR Signaling: Insights into Biological Functions and Disease Relevance
by: Oshadi Edirisinghe, et al.
Published: (2024-12-01) -
Reprogramming FGF1 from the natural growth factor to the engineered heparan sulphate biosensor
by: Krzysztof Ciura, et al.
Published: (2025-05-01) -
Genetically-engineered Salmonella typhimurium expressing FGF21 promotes neurological recovery in ischemic stroke via FGFR1/AMPK/mTOR pathway
by: Dongchen Xu, et al.
Published: (2025-06-01) -
MYC alterations in multiple myeloma: Genetic insights and prognostic impact
by: Sara Cristóbal-Vargas, et al.
Published: (2025-08-01)